Table 1.
MTb epitopes and SPs domains used in this study and the proliferative response they induce:. Various peptides were assayed for proliferation using PBMC of 13 Healthy donor. SI represents an average of 8 different experiments using 13 different naïve donors. Percent positive represents patients with SI≥2. Bolded numbers represent groups significantly different from other groups responding to peptides in the same protein (Fisher exact P<0.05)
| Peptide details | Proliferation | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| MT peptide name | Antigen | Sequence | Location in protein | length (aa) | MT SP | Hum SP* | Donors ** | Percent positive | SI |
| VXL201 Total | Antigen 85B A5U3Q3 | MTDVSRKIRA WGRRLMIGTA AAVVLPGLVG LAGGAATAGA | 1–40 | 40 | Yes | Yes | 13 | 85% | 2.2 |
| VXL201a | QQFIYAGSLSALLDPSQGM | 181–199 | 19 | No | No | 6 | 50% | 1.97 | |
| VXL201b | YLQVPSPSMGRDIKVQFQ | 50–67 | 18 | No | No | 6 | 17% | 1.4 | |
| VXL201c | FSRPGLPVEYLQVPSPSM | 41–58 | 18 | No | No | 6 | 0% | 1.3 | |
| VXL203 Total | Lipoprotein lpqH P0A5J0 | MKRGLTVAVA GAAILVAGLS GCSS | 1–42 | 24 | Yes | Yes | 13 | 54% | 2 |
| VXL203 Pure | 1–42 | 24 | Yes | Yes | 9 | 56% | 5.4 | ||
| VXL203a | AATGIAAVLT DGNPPEVKSV GLGN | 81–104 | 24 | No | No | 6 | 50% | 2 | |
| VXL208 Total | ATP dependent helicase putative CDC1551 | MRFAQPSALS RFSALTRDWF TSTFAAPTAA QA | 1–32 | 32 | Yes | Yes | 13 | 77% | 2.6 |
| VXL208 Pure | 1–32 | 32 | Yes | Yes | 9 | 66% | 5.4 | ||
| VXL208a | EVLRILRRRS LAALRAQAEP VSTAAYGRFL PA | 1172–1203 | 32 | No | No | 6 | 0% | 1.7 | |
| VXL211 Total | Un char protein Rv0476/MTO4941 prec P64695 | MLVLLVAVLVTAVYAFVHA | 1–19 | 19 | Yes | Yes | 13 | 85% | 2.71 |
| VXL211 Pure | 1–19 | 19 | Yes | Yes | 9 | 78% | 5.3 | ||
| VXL211a | MSACASGV YLVDVRPKLL E | 63–81 | 19 | No | No | 6 | 0% | 1.6 | |
| VXL211b | AMSACASGV YLVDVRPKLL | 62–80 | 19 | No | No | 6 | 0% | 1.3 | |
| VXL212 Total | Un char protein Rv1334/MT1376 prec P64813 | MLLRKGTVYVLVIRADLVNAMVAHA | 1–25 | 25 | Yes | Yes | 13 | 54% | 1.94 |
| VXL212 Pure | 1–25 | 25 | Yes | Yes | 9 | 78% | 3.4 | ||
| VXL212a | TEAYPSRT DVKLATEPDA HYVLVST | 93–117 | 25 | No | No | 6 | 0% | 1.3 | |
| VXL212b | P DEACGVLAGP EGSDRPERHI PMTN | 30–54 | 25 | No | No | 6 | 0% | 1.1 | |
| Total SP sequences | 140 (tot) | Yes | Yes | 65 | 56% | ||||
| Total non-SP sequences | 199 (tot) | No | No | 90 | 13% | ||||
*
Vaccine’s sequence represent the human SP (mTb) SP is usually longer.
**
Bold represent significant differences between observed and expected SP and non-SP sequences (P<0.015 or lower)